Brief: Transgene Announces Financial Visibility Until 2022

Transgene SA

10/03/2021 17:08

March 10 (Reuters) - TRANSGENE SA  TRNG.PA :
    * TRANSGENE: SIGNIFICANT MILESTONES ACHIEVED ON ALL DRUG
CANDIDATES IN 2020 AND FINANCIAL VISIBILITY UNTIL 2022
    * TG4050: FIRST PATIENTS TREATED IN TWO CLINICAL TRIALS OF
NOVEL
INDIVIDUALIZED IMMUNOTHERAPY BASED ON MYVAC® TECHNOLOGY - FIRST
DATA EXPECTED IN 4Q 2021
    * TG4001: EXPANDED RANDOMIZED PHASE II TRIAL TO START IN
HPV-POSITIVE ANOGENITAL CANCERS, BASED ON ENCOURAGING PHASE
IB/II DATA
    * BT-001: FIRST CANDIDATE FROM INVIR.IO™ PLATFORMHAS ENTERED
CLINIC
    * FINANCIAL VISIBILITY UNTIL 2022 FOLLOWING PARTIAL SALE OF
STAKE
IN TASLY BIOPHARMACEUTICALS IN 2020
    * RANDOMIZED PHASE II TRIAL OF TG4001 IN HPV16-POSITIVE
ANOGENITAL
CANCERS TO START, BASED ON PROMISING INITIAL DATA FROM PHASE
IB/II
    * BT-001, FIRST ONCOLYTIC VIRUS BASED ON INVIR.IO™, HAS
ENTERED
CLINIC AND FIRST OBSERVATIONS FROM TG6002 CONFIRM POTENTIAL OF
OUR NEXT-GENERATION ONCOLYTIC VIRUSES
    * OUR COLLABORATION WITH ASTRAZENECA CONTINUES TO DEVELOP
NEW
INNOVATIVE ONCOLYTIC VIRUSES
    * ASTRAZENECA CAN EXERCISE AN OPTION TO FURTHER DEVELOP EACH
OF
THESE NOVEL DRUG CANDIDATES IN CLINIC
    * OPERATING INCOME OF EUR 9.9 MILLION IN 2020, COMPARED TO
EUR
13.7 MILLION IN 2019
    * NET LOSS OF EUR 17.2 MILLION IN 2020, COMPARED TO EUR 18.8
MILLION IN 2019
    * CASH AVAILABLE AT YEAR-END 2020: EUR 26.3 MILLION,
COMPARED TO
EUR 43.3 MILLION AT END OF 2019
    * NET OPERATING EXPENSES OF EUR 33.9 MILLION IN 2020,
COMPARED TO
EUR 39.2 MILLION IN 2019
    * FINANCIAL INCOME OF EUR 6.8 MILLION IN 2020, COMPARED TO
EUR 6.7
MILLION IN 2019

Source text for Eikon:  ID:nBw1GJNkpa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))